Skip to main content

Table 6 Utility decrements

From: Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece

Event Values Reference
Ischemic heart disease −0.090 [29]
Myocardial infarction (non fatal) −0.055 [29]
Congestive heart failure −0.108 [29]
Stroke (non fatal) −0.164 [29]
Amputation −0.280 [29]
Renal failure −0.379 [30]
Symptomatic hypoglycemia risk −0.014 [32]
Severe hypoglycemia −0.047 [32]
Weight increase (per kg) −0.002 [31]